JP7483630B2 - 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 - Google Patents

神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 Download PDF

Info

Publication number
JP7483630B2
JP7483630B2 JP2020562548A JP2020562548A JP7483630B2 JP 7483630 B2 JP7483630 B2 JP 7483630B2 JP 2020562548 A JP2020562548 A JP 2020562548A JP 2020562548 A JP2020562548 A JP 2020562548A JP 7483630 B2 JP7483630 B2 JP 7483630B2
Authority
JP
Japan
Prior art keywords
ketamine
neurodevelopmental disorder
therapeutic agent
cognitive dysfunction
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562548A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020138491A1 (https=
JPWO2020138491A5 (https=
Inventor
謙二 橋本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
Original Assignee
Chiba University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC filed Critical Chiba University NUC
Publication of JPWO2020138491A1 publication Critical patent/JPWO2020138491A1/ja
Publication of JPWO2020138491A5 publication Critical patent/JPWO2020138491A5/ja
Application granted granted Critical
Publication of JP7483630B2 publication Critical patent/JP7483630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020562548A 2018-12-27 2019-12-27 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 Active JP7483630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018245688 2018-12-27
JP2018245688 2018-12-27
PCT/JP2019/051605 WO2020138491A1 (ja) 2018-12-27 2019-12-27 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体

Publications (3)

Publication Number Publication Date
JPWO2020138491A1 JPWO2020138491A1 (https=) 2020-07-02
JPWO2020138491A5 JPWO2020138491A5 (https=) 2023-01-11
JP7483630B2 true JP7483630B2 (ja) 2024-05-15

Family

ID=71127068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562548A Active JP7483630B2 (ja) 2018-12-27 2019-12-27 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体

Country Status (4)

Country Link
US (1) US20220110889A1 (https=)
EP (1) EP3903775A4 (https=)
JP (1) JP7483630B2 (https=)
WO (1) WO2020138491A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
CN118647595A (zh) 2021-10-12 2024-09-13 感知神经科学公司 R-氯胺酮盐及其使用方法
CA3245931A1 (en) 2022-03-14 2023-09-21 Perception Neuroscience, Inc. R-KETAMINE PHARMACEUTICAL FORMULATIONS
JP2023152104A (ja) * 2022-04-01 2023-10-16 株式会社エル・エスコーポレーション 認知機能の評価方法、及び、認知機能の評価装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150196501A1 (en) 2014-01-14 2015-07-16 Children's Hospital Medical Center Compositions and methods for treating an autism spectrum disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SI3043785T1 (sl) * 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
JP2020506231A (ja) * 2017-01-31 2020-02-27 パオロ エル マンフレディ 神経系の障害並びにその症状及び徴候の処置又は予防のため並びに疾患及び細胞の老化並びにその症状及び徴候に対する細胞保護のための化合物
WO2019065900A1 (ja) * 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150196501A1 (en) 2014-01-14 2015-07-16 Children's Hospital Medical Center Compositions and methods for treating an autism spectrum disorder

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JHONSON K. M. et al.，Phencyclidine: it ain’t excitin’, but it sure is toxic，13th International Congress on Amino Acids, peptides and proteins，2013年08月14日，Vol.45，pp.588-589
MOHAMMADI A. et al.，Dysfunction in Brain-Derived Neurotrophic Factor Signaling Pathway and susceptibility to Schizophren，Curr. Gene Ther.，2018年05月，Vol.18，pp.45-63
YANG C. et al.，R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects，Transl. Psychiatry，2015年09月01日，Vol.5，Article Number:e632, pp.1-11，doi: 10.1038/tp.2015.136

Also Published As

Publication number Publication date
JPWO2020138491A1 (https=) 2020-07-02
US20220110889A1 (en) 2022-04-14
EP3903775A4 (en) 2022-10-12
WO2020138491A1 (ja) 2020-07-02
EP3903775A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
JP7483630B2 (ja) 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
JP7627514B2 (ja) Ｒ－ケタミンおよびその塩の医薬品としての応用
EP2164572B1 (en) Carbamoyl-cyclohexanes for treating acute mania
JP7245509B2 (ja) 吃音を治療するための融合ベンズアゼピン
JP2009531435A (ja) うつ病の治療用の新規な治療組み合わせ
EP3689340A1 (en) R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
CN104955483A (zh) 用低剂量药剂治疗抑郁症和其它疾病
US20220023316A1 (en) Methods for the treatment of depression
CN113301894A (zh) mGluR5拮抗剂用于治疗阿片类物质镇痛耐受性的用途
TW201605856A (zh) ５－ＨＴｃ受體促效劑
HK40063625A (en) R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
US20230372364A1 (en) Method of treating gaba mediated disorders
WO2021010348A1 (ja) うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１
Raudino et al. Gabapentin and behavioral disorders in severe Alzheimer disease
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
Works standard treatments for OSAHS; if continuous positive airway pressure (CPAP) is the treatment of choice, a maximal effort to treat first with
Best apnea/hypopnea syndrome (OSAHS)
Baldessarini et al. LITHIUM (continued)
Behere et al. Clinical Psychopharmacology
Works How Long Until It Works
Ratchford Dementia, HIV-associated
Jefferson Comments on article by Harrigan et al:" A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition."
Dandiya et al. BENZODIAZEPINES: THEIR PHARMACOLOGICAL BASIS AND PRESENT STATUS IN THERAPY
HK40033382A (en) R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
Works Brands• Latuda

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240501

R150 Certificate of patent or registration of utility model

Ref document number: 7483630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150